Dose-Ranging Study Evaluating AVE1625 in Abdominally Obese Patients With Atherogenic Dyslipidemia

Exclusion Criteria

• •Pregnancy or lactation
• •Women of child-bearing potential with no medically approved contraception
• •Patients with type 1 diabetes
• •Patients with type 2 diabetes must be on a stable dose of oral antidiabetic drugs (excluding glitazones, exenatide, sulfonylurea and nateglinide) and should not receive insulin therapy
• •Patients with any clinically significant endocrine disease
• •Patients on anticoagulants (heparin, warfarin) or with bleeding disorders
• •Clinically relevant disease interfering with subject's safety or making implementation of the study protocol or interpretation of study results difficult
• •Patients with mental retardation or any clinically significant psychiatric disorder
• •History or concurrent substance abuse (other than nicotine or caffeine especially marijuana or hashish)
• •Chronic systemic corticotherapy
• •Patients with weight change \> 5kg within 3 months prior to screening
• •Patients should not have received anti-obesity drugs or other drugs for weight reduction in the 3 months prior to screening.
• •The investigator will evaluate whether there are other reasons why a patient may not participate